

Evaluating the impact of outcome delay on the efficiency of two-arm group-sequential trials

Aritra Mukherjee¹, Michael J. Grayling², and James M. S. Wason¹

¹Population Health Sciences Institute, Newcastle University

²Janssen R&D

Abstract

Background: Adaptive designs are a broad class of designs that allow modifications to be made to a trial as patient data is accrued. Adaptive designs can offer improved efficiency and flexibility. However, a delay in observing the primary outcome variable can potentially harm the efficiency added by adaptive designs. Principally, in the presence of such delay, we may have to make a choice as to whether to (a) pause recruitment until requisite data is accrued for the interim analysis, leading to a longer study duration; or (b) continue to recruit patients, which may result in a large number of participants who do not benefit from the interim analysis and damage to the study's efficiency. Little work has been conducted to ascertain the size of outcome delay that results in the realised efficiency gains of adaptive designs becoming negligible compared to classical fixed-sample alternatives. We perform such work here for two-arm group-sequential designs (GSDs) with different numbers of interim analyses.

Methods: We measure the impact of outcome delay by developing formulae for the number of 'overruns' (sometimes called 'pipeline' patients) in two-arm GSDs with normal data, assuming different recruitment models. Typically, the efficiency of a GSD is measured in terms of the expected sample size (ESS), with GSDs generally reducing the ESS compared to a design without interim analyses. Our formulae enable us to measure the efficiency gain from a GSD in terms of ESS reduction that is lost due to outcome delay. We assess whether careful choice of design (e.g., altering the spacing of the interim analyses) can help recover the advantages of GSDs in the presence of outcome delay. We similarly analyse the efficiency of GSDs with respect to time to complete the trial.

Results: On comparing the expected efficiency gains, with and without consideration of the impact of delay, it is evident GSDs can suffer considerable losses due to outcome delay. Even a small delay can have a considerable impact on the trial's efficiency in terms of an increased EL. On the other hand, even in the presence of substantial delay, a GSD will have a smaller expected time to trial completion in comparison to a single-stage trial. Although the number of stages have very less influence on the efficiency losses, the timing of the interim analysis can considerably impact the efficiency of a GSD in presence of delay.

Conclusions: A delay in observing the treatment outcome is harmful to the efficiency of a GSD. Even a small delay in presence of an increasing recruitment pattern can incur heavy losses to the design. Furthermore, with unequally spaced interims, pushing analyses towards the latter end of the trial can potentially be harmful for the design in the presence of delay.

Keywords: Adaptive design; Interim analysis; Multi-stage; Two-stage.

1 Introduction

Group-sequential designs (GSDs) are commonly used in practice for two-arm randomised controlled trials (RCTs), particularly in the later phases of drug development [1, 2]. A GSD introduces interim analyses (IAs) that allow early termination for efficacy or futility based on the accumulating data [3, 4, 5, 6]. They have the potential to improve efficiency (e.g., in terms of the study’s expected time to completion or required sample size) considerably compared to a classical design with a single analysis. Further, as the number of stages increases, a greater efficiency gain is expected due to increased reduction in the expected sample size (ESS) [3, 7].

However, long-term endpoints can heavily impact the potential advantages of GSD. A delay in observing a treatment outcome will often either (a) increase the time to complete the trial if recruitment is paused at each IA to await collection of all outcome data, or (b) inflate the cost of the trial by recruiting a potentially larger number of patients than needed if recruitment is continued [8]. For example, consider a trial that is testing a drug against the existing standard of care with 80% power and 5% significance level[two-sided] for a standardised effect size of 0.4. The primary outcome is measured after one year from starting the treatment. Then for a three-stage GSD using O’Brien and Fleming stopping boundaries [9], the required sample size at stage 1, 2 and 3 is 66, 134 and 200 respectively, with the corresponding single stage sample size being 196 participants. If the trial aims to complete recruitment by 2 years, then the required rate of recruitment is approximately 8 patients per month. Assuming 8 patients are recruited per month, then at the first IA, by the time outcome data is available from the first 66 patients, the trial would have recruited an additional 96 patients if recruitment is not paused. If the trial stops at the IA, then these 96 patients were enrolled and treated needlessly.

As the time to observe the primary outcome becomes larger (or the recruitment rate becomes faster), this would lead to an even less efficient design.

Recently, Mukherjee et al. [10] evaluated the impact of outcome delay on two-stage single-arm trials, as are commonly employed in phase 2 oncology trials. It was observed that Simon’s two-stage design may be preferable over a corresponding single-stage alternative if the ratio of the delay period to the recruitment length is less than 0.25. Extension of this work to randomised two-arm GSDs (which may more typically have more than two stages) is needed. Hampson and Jennison [11] discussed outcome delay within the context of two-arm GSDs. They described in detail how delay can impact a GSD with equally spaced IAs, when recruitment occurs at a constant rate (i.e., patient recruitment follows a Poisson arrival process). They proposed a sequential test

structure incorporating the outcome delay and further provided an optimal test to minimise the ESS. Nonetheless, they also noted out that the benefits of lower ESS that are normally achieved by a GSD are reduced when there is a delay in outcome accrual, even when an optimal design is used. Further work is needed to explore how the delay length and recruitment speed impacts on efficiency, and how this is affected by the number and spacing of interim analyses.

In this study, we aim to clearly quantify the loss in efficiency provided by a GSD for a given delay in the treatment outcome. Building on Hampson and Jennison’s observation, we also seek to examine how different numbers of IAs, and the timing of these IAs, can impact the efficiency of the design. In addition to considering the ESS, we also study the impact of outcome delay on the expected time to trial completion when using a GSD.

2 Methods

2.1 Design and notation

We consider a two-arm GSD for testing superiority of an experimental treatment over a control. Let n_{0k} and n_{1k} denote the cumulative sample size at stage k , $k = 1, 2, \dots, K$, for the control and treatment arms respectively. Thus we assume the design has at most K stages. Further, let $n_k = n_{0k} + n_{1k}$.

For illustration, we assume the treatment response from participant $i = 1, 2, \dots, n_{jK}$ in arm $j = 0, 1$ is distributed as $X_{ij} \sim N(\mu_j, \sigma_j^2)$, with σ_0 and σ_1 known. Extension to many other types of outcome (e.g., binary, count) follows naturally if test statistics follow the canonical joint distribution described by Jennison and Turnbull[3]. We suppose the trial is powered to test the hypothesis $H_0 : \mu \leq 0$ against $H_1 : \mu > 0$, for $\mu = \mu_1 - \mu_0$, at significance level α , with power $1 - \beta$ when $\mu = \tau > 0$.

At IA k , the test statistic used is

$$Z_k = \frac{\frac{1}{n_{1k}} \sum_{i=1}^{n_{1k}} X_{i1} - \frac{1}{n_{0k}} \sum_{i=1}^{n_{0k}} X_{i0}}{\sqrt{\frac{\sigma_0^2}{n_{0k}} + \frac{\sigma_1^2}{n_{1k}}}}.$$

The GSD is assumed to use efficacy and (binding) futility stopping boundaries. There are many approaches available to determine these stopping boundaries, including Pocock’s [12], O’Brien-Fleming’s [9], and Wang-Tsiatis’[13] methods. Alternatively, an α -spending approach may be adopted, where the boundaries at stage k are dependent on the proportion, ρ_k , of the maximal Fisher’s information that is available at IA k . If we denote the efficacy and futility boundaries used at analysis k , determined by a given method, by e_k and f_k , then the following stopping rules are used

- stop at IA k for efficacy if $Z_k > e_k$;
- stop at IA k for futility if $Z_k \leq f_k$;

- continue to IA $k + 1$ if $f_k < Z_k \leq e_k$.

Next, define

$$\begin{aligned} E_k(\mu) &= P(\text{Accept } H_0 \text{ at stage } k|\mu), \\ F_k(\mu) &= P(\text{Reject } H_0 \text{ at stage } k|\mu), \\ S_k(\mu) &= P(\text{Trial terminates after stage } k|\mu), \\ &= E_k(\mu) + F_k(\mu). \end{aligned}$$

Then, the ESS for a GSD is often stated as

$$\begin{aligned} ESS(\mu) &= \sum_{k=1}^K \{E_k(\mu) + F_k(\mu)\}n_k, \\ &= \sum_{k=1}^K S_k(\mu)n_k. \end{aligned}$$

Therefore, the expected efficiency gain (EG) from using a GSD instead of a corresponding single-stage design can be calculated as

$$EG(\mu) = \frac{n_{\text{single}} - ESS(\mu)}{n_{\text{single}}},$$

where n_{single} is the required sample size for the single-stage design.

2.2 Efficiency accounting for outcome delay

The formula above for the ESS ignores the potential issue of outcome delay (i.e., it essentially assumes that outcome X_{ij} is accrued immediately after recruitment). To extend the formulae above to allow for outcome delay, we suppose that responses are available a time m after a patient is recruited. If we assume that recruitment is not paused for the conduct of each IA, there will then be additional participants recruited between the recruitment of participant n_k and the conduct of IA k (these are often referred to as ‘pipeline’ participants). We will denote this random variable, i.e., the number of such pipeline participants at the time of IA k by \tilde{n}_k for $k = 1, 2, \dots, K - 1$. We assume that recruitment stops when n_K patients have been recruited, such that there can be no pipeline participants at analysis K .

To quantify the efficiency lost due to delay, we therefore require expected values for the \tilde{n}_k . These values will depend on the delay length m , but also on the recruitment model. They will be the focus of the coming sections, where we define a framework in which recruitment will be a function of parameters δ , l , and t_{max} , to be defined later. Accordingly, we have $\tilde{n}_k = \tilde{n}_k(m, \delta, l, t_{\text{max}})$ and the

ESS when accounting for outcome delay will then be given by

$$\begin{aligned} ESS_{\text{delay}}(\mu, m, \delta, l, t_{\max}) &= \sum_{k=1}^{K-1} \{E_k(\mu) + F_k(\mu)\}(n_k + \tilde{n}_k) \\ &\quad + \{E_K(\mu) + F_K(\mu)\}n_K, \\ &= \sum_{k=1}^{K-1} S_k(\mu) (n_k + \tilde{n}_k) + S_K(\mu) n_K. \end{aligned}$$

Thus, the ‘true’ efficiency gained (EG) compared to a single-stage design in the presence of outcome delay will be measured as

$$EG_{\text{Delay}}(\mu, m, \delta, l, t_{\max}) = \frac{n_{\text{single}} - ESS_{\text{Delay}}(\mu, m, \delta, l, t_{\max})}{n_{\text{single}}}.$$

We will then quantify the efficiency loss (EL) due to outcome delay as the percentage change in the EG when considering delay in comparison to not considering delay. That is

$$EL(\mu, m, \delta, l, t_{\max}) = 100 \frac{EG(\mu) - EG_{\text{delay}}(\mu, m, \delta, l, t_{\max})}{EG(\mu)}.$$

The value of EL is typically expected to be less than or equal to 100, however, it is possible to observe a value greater than 100 if the delay makes the group sequential design less efficient than the single stage design.

2.3 Computing the number of pipeline participants

We consider two sub-cases for estimating the number of pipeline participants at a given IA. From here onward, we consider time to be a discrete variable, as previous work indicates minimal difference from treating time as continuous. Further, GSDs usually tend to be long trials, which makes the formulae simpler to communicate and comprehend, when time is assumed to be discrete. We also assume the unit of time to be months. The results could also be readily generalised for other units of time, given all the parameters are defined in the same units.

2.3.1 Uniform recruitment

We consider a uniform recruitment pattern with rate of recruitment λ . We suppose it takes t_{\max} months to recruit all n_K patients. Then, for uniform recruitment, the expected number of pipeline participants at each IA should typically be constant, say \tilde{n} . However, we must account for the fact that the number of pipeline participants cannot lead to the total sample size of the trial being above n_K . Thus, in this case

$$\tilde{n}_k = \begin{cases} \tilde{n} & : \tilde{n} \leq n_K - n_k, \\ n_K - n_k & : \tilde{n} > n_K - n_k, \end{cases}$$




Figure 1: Recruitment model for the ‘mixed’ recruitment pattern.

where

$$\tilde{n} = \lambda m = \frac{n_K}{t_{\max}} m.$$

2.3.2 ‘Mixed’ recruitment

In reality, uniform participant recruitment may poorly reflect recruitment rates observed in practice. This is because early in a trial, sites are gradually opened until a maximum number is reached. We allow for this by assuming participants are recruited at time t in a linearly increasing pattern (at rate $\lambda = \delta t$) up to l times of the total recruitment length t_{\max} , $0 < l \leq 1$ (see Figure 1). For times above lt_{\max} , we assume the recruitment pattern is then uniform, with $\lambda = \delta lt_{\max}$. We refer to this more general pattern of recruitment as ‘mixed recruitment’. Note that when $l = 1$ we observe a continuously linearly increasing recruitment pattern; we will refer to this special case later as ‘linear recruitment’. We assume throughout that (assumed) values for l and t_{\max} have been specified, reflecting the common practice at the design stage of any study in which recruitment must be projected.

Next, denote by t_k the expected amount of time taken to recruit n_k patients. Then, \tilde{n}_k will depend on t_k , m , δ , and l .

Observe that under the above recruitment model, in t_{\max} months the total number of recruitments

is expected to be

$$\begin{aligned} & \delta(1 + 2 + \dots + lt_{\max}) + \delta lt_{\max}(1 - l)t_{\max} \\ & = 0.5\delta lt_{\max}(lt_{\max} + 1) + \delta lt_{\max}(1 - l)t_{\max}. \end{aligned}$$

As this value should equal the maximum sample size n_K , this provides us with an estimate for δ , as the other quantities in the above formula are fixed.

To compute general estimates for the \tilde{n}_k , we must account for several possibilities, based on the location of lt_{\max} in the recruitment rate.

- If $lt_{\max} < t_1$, i.e., the first IA happens after the recruitment rate becomes uniform, then the expected number of pipeline participants at each IA remains constant due to the uniform recruitment pattern and takes the value $\tilde{n}_k = \delta lt_{\max}m$.
- When lt_{\max} lies between IA i and $i + 1$, i.e., $t_i \leq lt_{\max} < t_{i+1}$ for $i = 1, 2, \dots, K - 2$, then $\tilde{n}_k = \delta lt_{\max}m$ for $k = (i + 1), (i + 2), \dots, (K - 1)$, due to the uniform recruitment pattern. (Note that for $i = K - 1$, there would be no pipeline participants at analysis $i + 1 = K$ as this is the final stage of the trial.)

For the expected number of pipeline subjects for IA $k = 1, 2, \dots, i$, we need the values of t_k , $k = 1, 2, \dots, i$ as the recruitment is assumed to be linear for IA $k = 1, 2, \dots, i$.

It can be computed as

$$\begin{aligned} \delta(1 + 2 + \dots + t_k) &= n_k \\ \text{or, } \delta \frac{t_k(t_k + 1)}{2} &= n_k \end{aligned}$$

Solving the quadratic in t_k gives

$$t_k = -0.5 + 0.5\sqrt{\left(1 + \frac{4 * 2n_k}{\delta}\right)}$$

Then, the expected number of pipeline patients for IA $k, k = 1, 2, \dots, (i - 1)$ is given by

$$\begin{aligned} \tilde{n}_k &= \delta\{(t_k + 1) + (t_k + 2) + \dots + (t_k + m)\}, \\ &= \delta m t_k + \delta m(m + 1)/2. \end{aligned}$$

For $k = i$, the value of \tilde{n}_k depends on the location of lt_{\max} as follows

1. If $t_i + m < lt_{\max}$, then the pipeline participants are obtained from assuming linearly increasing recruitment as in the previous case,

$$\begin{aligned}\tilde{n}_i &= \delta\{(t_i + 1) + (t_i + 2) + \cdots + (t_i + m)\}, \\ &= \delta mt_i + \delta m(m + 1)/2.\end{aligned}$$

2. If $t_i + m \geq lt_{\max}$ then the pipeline participants are obtained from assuming linearly recruitment first and uniform recruitment for the remaining time. This gives

$$\begin{aligned}\tilde{n}_i &= \delta\{(t_i + 1) + (t_i + 2) + \cdots + lt_{\max}\} \\ &\quad + \delta lt_{\max}(t_i + m - lt_{\max}).\end{aligned}$$

Therefore, in summary, for $i = 1, 2, \dots, K - 2$, the number of pipeline subjects can be found as in table 1.

IA	Position of lt_{\max}	Estimate of pipeline subjects
$k = 1, 2, \dots, (i - 1)$		$\tilde{n}_k = \delta mt_k + \delta m(m + 1)/2$
$k = i$	$t_i + m < lt_{\max}$ $t_i + m \geq lt_{\max}$	$\tilde{n}_i = \delta mt_i + \delta m(m + 1)/2$ $\tilde{n}_i = \delta\{(t_i + 1) + (t_i + 2) + \cdots + lt_{\max}\} + \delta lt_{\max}(t_i + m - lt_{\max}).$
$k = (i + 1), (i + 2), \dots, K - 1$		$\tilde{n}_k = \delta lt_{\max} m$

2.4 Impact of delay on expected time to trial completion

So far, we have considered the ESS as the measure of efficiency for analysing the impact of outcome delay on the trial design. However, particularly in clinical trials sponsored by the pharmaceutical industry, the primary measure of optimality, might not be a reduced ESS but the overall time to complete the trial. In this section, we therefore explore how a delay in observing the treatment outcome impacts the expected time to complete the trial.

Let us denote by T the time to complete a trial for a K stage design. Now, at IA k , T is given by the sum of the total time to recruit stage k patients (say, t_k) and time to observe their treatment outcome (m, say); $k = 1, 2, \dots, K$

Let us assume for a group-sequential design with K stages, the sample size at stage k is given by n_k , $k = 1, 2, \dots, K$. Suppose, the patients are being recruited uniformly over a total recruitment period of t_{\max} .

Then the time taken to recruit all the patients (n_k) for stage k would be given as

$$t_k = \frac{t_{\max}}{n_K} n_k, \quad k = 1, 2, \dots, K.$$

If we consider the delay into account then, the expected time to complete the trial can be given as

$$\begin{aligned} ET(\mu) &= \sum_{k=1}^K (t_k + m) S_k(\mu) \\ &= m + \sum_{k=1}^K t_k S_k(\mu) \\ &= m + \sum_{k=1}^K \frac{t_{\max}}{n_K} n_k S_k(\mu) \\ &= m + \frac{t_{\max}}{n_K} ESS(\mu). \end{aligned}$$

If we consider that the IA will take some time to conduct, say $m_{interim}$ then, this quantity will only add up in the above equation.

Therefore, under the assumption that the recruitment is uniform the expected time to complete a trial is a linear function of the ESS.

For linearly increasing recruitment pattern, if t_k denote the time to recruit n_k patients then

$$\begin{aligned} \delta(1 + 2 + \dots + t_k) &= n_k \\ \Rightarrow \frac{\delta t_k(t_k + 1)}{2} &= n_k \\ \Rightarrow t_k &= \frac{-1 + \sqrt{1 + \frac{8n_k}{\delta}}}{2}. \end{aligned}$$

Thus

$$\delta = \frac{2n_K}{t_{\max}(t_{\max} + 1)}.$$

If we assume the same recruitment rate as before, the expected time to complete a single stage trial is given by: the time taken to recruit the total number of patients n_{single} plus the time taken to observe their treatment outcome (m).

The above results show that, given a total recruitment period, the time to complete a trial is a linear function of ESS or a function of lower degree of the sample size at each stage. We know that a group-sequential trial without delay always provides a benefit in terms of lower expected sample size, compared to a single stage trial. Since the expected time to complete a trial is a linear function

of the ESS or a function in sample size of lower degree, the time to complete the trial will always be lower than that of a single stage design, assuming a similar recruitment rate.

Therefore, it is always beneficial to conduct a group-sequential trial if the efficiency metric is the time to complete a trial.

2.5 Examples

Although the expected time to complete the trial gives definitive answers when a group sequential is beneficial, the efficiency gain in terms of ESS in presence of delay still remains under investigation. Therefore the following section provides a roadmap to different simulation scenario for assessing the impact of delay on group sequential trials.

For our study, we have considered both equally and unequally spaced IAs with uniform, linear, and mixed recruitment patterns. In practice, most trials using a GSD have a maximum of $K = 5$ stages [14]. Therefore, we focused our results on designs with $K = 2, 3, 4$, or 5 .

Throughout, we set $\alpha = 0.05$, $\beta = 0.1$, and $\mu = \tau = 0.5$ (i.e., the EL is evaluated under the target effect). Also, we assume equal allocation to the experimental and control arms (i.e., $n_{0k} = n_{1k}$ for $k = 1, 2, \dots, K$) and $\sigma_0^2 = \sigma_1^2 = 1$.

The total recruitment period is assumed to be $t_{\max} = 24$ months and we provide results for varying delay periods up to 24 months. (Exact EL values are provided for delay length of $m = 3, 6, 9, 12, 18$, and 24 months in the supplementary materials.) For the mixed recruitment pattern, in all of the above cases we considered scenarios when $l = 0.2, 0.4, 0.6, 0.8$, i.e., the trials had a linear recruitment rate for 20, 40, 60, or 80% of the total recruitment period.

For unequally spaced IAs, we have considered four different combinations of IA spacings in the 3 stage design setting. Specifically, we assumed the information fractions (ρ_1, ρ_2, ρ_3) to be $(1/3, 2/3, 1)$, $(1/4, 1/2, 1)$, $(1/2, 3/4, 1)$, or $(6/10, 9/10, 1)$. For 4 stage designs, we similarly considered different combinations for IA spacing viz. $(\rho_1, \rho_2, \rho_3, \rho_4)$ to be $(1/4, 2/4, 3/4, 1)$, $(1/5, 2/5, 3/5, 1)$, $(2/5, 3/5, 4/5, 1)$

R code to reproduce our analyses is available from <https://github.com/AritraMukherjee/GroupSequentialDesign.git>.

3 Results

3.1 Impact of delay on expected sample size

First, we quantify the efficiency lost in terms of ESS as a result of delay in observing treatment outcomes. We subset our results by the spacing of the IAs.

3.1.1 Equally spaced interim analyses

The following subsection contains results assuming GSDs with Wang-Tsiatis boundaries [13]; the value of the shape parameter is assumed to be 0.25. Results for other boundary shapes (e.g., Pocock, O'Brien-Fleming) can be found in the Supplementary Material.

From Figure 2, it can be observed that as m increases, there is an increasing EL due to delay. An EL of 100%, indicates that the EG expected for using a GSD is completely lost due to delay, i.e. the value of ESS_{delay} is same as the single stage sample size. For even higher EL values, the ESS_{delay} is even greater than n_{single} , where ESS_{delay} attains the maximum possible sample size for the design. A linearly increasing recruitment pattern incurs heavy efficiency loss, when compared to a uniform recruitment pattern, even for smaller delay lengths due to the recruitment pattern. The EL attains a close but, distinct maximum value for each K as ESS_{delay} can attain a constant maximum value (the maximum sample size), based on the design. The EL appears to be similar for different number of stages, especially for $K = 3, 4$ and 5 . Since, the recruitment period is assumed to be 24 months for all the designs and the maximum sample size for different number of stages, varies by a very small amount, the recruitment rate remains similar for designs with different K . Therefore, a similar EL can be observed for varying K . However, it can be observed that although by a very small amount, having a 2-stage design can be beneficial in terms of reduced EL, for relatively smaller delay lengths (less than 10 months for uniform and less than 6 months for linear recruitment). For m greater than 4 months, almost 50% of the expected EG is typically lost due to delay for all of the GSDs.

For almost all of the K values, the minimum value m needed for a GSD to attain it's maximal EL is 15 months for uniform recruitment and for a linear recruitment the maximum EL is attained even sooner (at approximately 12 months).

For uniform recruitment with small delay ($m = 2$), the maximum loss observed is 23.55% for $K = 5$ and the minimum is 19.44% for $K = 2$. The same values for linearly increasing recruitment are 36.17% for $K = 5$ and 28.50% for $K = 2$ respectively. Therefore, for smaller delay lengths, GSDs retain most of their efficiency gain. On the other hand, the maximum EL observed is 122.33% for a 5-stage design when the delay length is greater than 14 months ($m > 15$), under both uniform and linear recruitment.

For the mixed recruitment pattern, we provide results for $l = 0.2, 0.4, 0.6$, and 0.8 . Findings for a 3-stage design are shown in Figure 3. It can be observed that the results obtained align with the findings in Figure 2, i.e., as the recruitment pattern becomes linear for a greater proportion of the total recruitment time, the EL increases. Further computations also indicate that, as the number of stages increases the EL is increased by a small amount [See supplementary materials] .

In summary, it was observed that if the delay length is more than 25% of the total recruitment period, at least 50% of the expected EG is lost due to delay for all recruitment patterns for 2-5 stage designs.




Figure 2: Efficiency loss (EL) due to delay, for different delay lengths m , assuming equally spaced interim analyses, under uniform and linear recruitment patterns.




Figure 3: Efficiency loss (EL) due to delay, for different delay lengths m , assuming equally spaced interim analyses in a 3-stage design, under a mixed recruitment pattern.

3.1.2 Unequally spaced interim analyses

For designs with unequally spaced IAs, we used an error-spending approach. Specifically, stopping boundaries were obtained using the Hwang-Shih-DeCani spending function with spending parameter -2 [15]. For three-stage designs, we considered four possible timings of the IAs under uniform and linear recruitment patterns. These were

1. $(1/3, 2/3, 1)$: IAs are equally spaced (I).
2. $(0.25, 0.5, 1)$: The IAs takes place sooner than under equal spacing (II).
3. $(0.5, 0.75, 1)$: The IAs take place later than under equal spacing (III).
4. $(0.6, 0.9, 1)$: The IAs occur even later than the design above (IV).

Figure 4 shows the results for the above scenarios.

It can be observed that, in general, the GSD with equally spaced IAs performs better than the GSDs with unequally spaced IAs. The exception to this is the case when the first IA is performed even sooner than that under equal spacing, i.e., the design where the two IAs are conducted at 25% and 50% of the total sample size incurs the smallest losses. If the first and subsequent IAs are pushed to the latter end of the trial the efficiency loss increases rapidly with the delay length. This is because, as we push the interims towards the latter end of the trial, we observe that the maximum sample size increases, thereby increasing the recruitment rate based on the assumptions of the recruitment model. For a linearly increasing recruitment this is further influenced by the factor that towards the end of the trial, there is a greater chance of larger numbers of pipeline samples




Figure 4: Efficiency loss (EL) due to delay for different delay lengths, in 3-stage designs with unequally spaced interim analyses, under uniform and linear recruitment patterns.

(as the recruitment pattern is increasing in nature). This in turn increases the number of pipeline patients and inflates the ESS_{delay} and EL.

We observe that EL crosses 100% for IA timings (0.6, 0.9, 1) for $m = 8$ in contrast to $m = 12$ for equally spaced interims. This EL occurs even sooner for a 5 month delay instead of 8 months, under linear recruitment. A maximal EL of 123.20% is observed for the IA timings (0.6, 0.9, 1) when the delay length is more than 10 months; this EL occurs even sooner for a 6 month delay, under linear recruitment.

We considered four-staged GSDs, under unequally spaced interims for different combinations of interim spacings. The results obtained are very similar to those for a three-stage design, i.e., if the first IA is pushed towards the latter end of the trial, the EL is increased when the delay length is sufficiently large (≥ 7 months). See the Supplementary Materials for these findings.

It is interesting to note that, if the recruitment period is fixed in advance, further computations also revealed that for any other choice of the recruitment period (e.g. 36 months), similar efficiency losses would be observed for similar values of $\frac{m}{t_{max}}$. i.e. the EL value remains similar for a 18 month delay for 36 month recruitment and a 12 month delay for 24 month recruitment. Therefore, the inferences can be generalised in terms of the ratio $\frac{m}{t_{max}}$.

4 Discussion

GSDs have been both widely used in practice and explored methodologically. However, little work has considered the impact of the time taken to observe the primary outcome variable when examining the utility of a GSD. This despite outcome delay being harmful to the efficiency of a GSD.

Our study therefore aimed to explore the extent to which group-sequential trials could be impacted by outcome delay. An EL was computed based on the difference in the efficiency gained over a single-stage trial without delay and with delay. We estimated the number of pipeline participants assuming uniform recruitment, linearly increasing recruitment, and under ‘mixed’ recruitment which combined these two patterns. Uniform recruitment is more likely a reasonable assumption for smaller scale single-centre trials, whereas mixed recruitment is more reasonable for large multi-centre trials, where the recruitment rate may increase as new centres open and reach a maximum rate once all centres are operational. A linearly increasing recruitment pattern can then be considered as an extreme case, where the recruitment rate never plateaus during the length of the enrollment.

We obtained results for different recruitment patterns and different delay lengths. They showed that, as would be expected, with an increase in the delay length the EL increases; this is a consequence of the fact that as delay increases so does the number of overruns, thereby increasing $ESS_{\text{delay}}(\cdot)$. The EL remains similar across designs with different values of K . However, a 2-stage design has marginally less efficiency lost compared to a 3, 4 or 5-stage design, especially when the ratio of outcome delay length to total recruitment length is less than 0.4 (or, 0.2 for linear recruitment). It was observed that, as $\frac{m}{t_{max}}$ takes values more than 0.5, GSDs incur heavy losses due to delay.

We also observed that the EL is typically greater under a linearly increasing recruitment pattern than for uniform recruitment, this follows from the increasing recruitment pattern leading to greater numbers of pipeline participants. A linear recruitment being one extreme of the mixed recruitment pattern, we observed that, as l increases (i.e., as the recruitment becomes linear for a longer period) a greater EL was observed, with the amount of loss observed lying between that under uniform and purely linear ($l = 1$) recruitment. Therefore, it can be said that, in real trials, the EL observed assuming a linear recruitment may be considered as a maximum EL possible for the design at a particular delay length.

We acknowledge that a limitation of our work is that our findings here are based only on a single combination of values for α , β , τ , and μ . In general, the EL will be dependent on these parameters. However, the Supplementary Materials contains additional findings that indicate the results altered little when we computed the EL for $\mu = 0.2$. In contrast, the EL tended to be lower for $\alpha = 0.01$ (instead of $\alpha = 0.05$), while it inflated further for $\beta = 0.2$ (instead of $\beta = 0.1$). Finally, the Supplementary Materials indicate how the shape of the stopping boundaries may impact the EL. The primary finding was that more aggressive stopping rule translates to larger EL, as it requires a bigger group size at each interim for the same power requirements, thereby impacting the number of pipeline patients.

For unequally spaced IAs, we considered several different possible spacings. It was observed that pushing the IAs towards the end of the trial can be harmful to the expected EG. The minimal EL was observed when the first IA was planned even sooner than that under equally spaced IAs. When the first IA is pushed toward the end, the EL increases with respect to a single stage design.

Therefore, the optimal choice for spacing the first IA is largely dependent on the delay length. If the delay length is relatively small, a conventionally design with equally spaced IAs should work well. Whereas, for a large delay length, the EL is reduced if the first IA is conducted very early.

We also considered the impact of outcome delay when the optimality criteria is the time to trial completion. In this case, GSDs always provide more benefit on average vs. a single-stage design, even if it takes a large time to observe the treatment outcome.

In summary, a delay in observing treatment outcomes decreases the expected EG from a GSD in terms of its reduction to the ESS. Typically, if the delay length is more than 25% of the total recruitment period, most of the efficiency gain in terms of ESS is lost due to delay. It might be best to use a two stage design if the ratio of time to observe the primary outcome to total recruitment period lies below 0.25 as the EL is comparatively lower than multistage GSD's. For designs with unequally spaced IAs, pushing the first IA towards the latter end of the trial can be harmful to the EG. However, if the optimality criteria is instead the time to trial completion, instead of the ESS, a GSD is beneficial regardless of the outcome length.

Acknowledgements

JMSW is funded by a NIHR Research Professorship (NIHR301614). AM is funded by a Newcastle University Overseas Research Scholarship (NUORS).

References

- [1] Hatfield I, Allison A, Flight L et al. Adaptive designs undertaken in clinical research: A review of registered clinical trials. *Trials* 2016; 17.
- [2] Bothwell L, Avorn J, Khan N et al. Adaptive design clinical trials: A review of the literature and ClinicalTrials.gov. *BMJ Open* 2018; 8.
- [3] Jennison C and Turnbull B. *Group sequential methods with applications to clinical trials*. New York, NY: Chapman and Hall/CRC, 2000.
- [4] Grayling M, Wason J and Mander A. Group sequential clinical trial designs for normally distributed outcome variables. *Stata J* 2018; 18: 416–431.
- [5] Kelly P, Sooriyarachchi M, Stallard N et al. A practical comparison of group-sequential and adaptive designs. *J Biopharm Stat* 2005; 15: 719–738.
- [6] Wason J. OptGS: An R package for finding near-optimal group-sequential designs. *J Stat Soft* 2015; 66: 1–13.
- [7] Wason J, Mander A and Thompson S. Optimal multistage designs for randomised clinical trials with continuous outcomes. *Stat Med* 2012; 31: 301–312.
- [8] Wason J, Brocklehurst P and Yap C. When to keep it simple - Adaptive designs are not always useful. *BMC Med* 2019; 17: 152.
- [9] O'Brien P and Fleming T. A multiple testing procedure for clinical trials. *Biometrics* 1979; 35: 549–556.
- [10] Mukherjee A, Wason J and Grayling M. When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay. *Eur J Cancer* 2022; 166: 270–278.
- [11] Hampson L and Jennison C. Group sequential tests for delayed responses. *J R Stat Soc B* 2013; 75: 3–54.
- [12] Pocock S. Group sequential methods in the design and analysis of clinical trials. *Biometrika* 1977; 64: 191–199.
- [13] Wang S and Tsiatis A. Approximately optimal one-parameter boundaries for group sequential trials. *Biometrics* 1987; 43: 193–199.


- [14] Stevely A, Dimairo M, Todd S et al. An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review. *PLoS One* 2015; 10.
- [15] Hwang I, Shih W and De Cani, JS. Group sequential designs using a family of type I error probability spending functions. *Stat Med* 1990; 9: 1439–1445.

Supplementary Materials to ‘Evaluating the impact of outcome delay on the efficiency of two-arm group-sequential trials’

1 Impact of other boundary shapes on efficiency loss

The following subsection contains results assuming a group-sequential design with Pocock and OBF boundaries. The results were obtained assuming $\alpha = 0.05, \beta = 0.1$ and target treatment effect, $\tau = 0.5$. The total recruitment time was assumed to be 24 months and efficiency lost was plotted for increasing delay length from 1 to 24 months.

Supplementary Figure 1 shows the efficiency lost due to delay for Pocock stopping boundaries whereas, Supplementary Figure 2 shows the same for a O’Brien-Fleming stopping boundary. The inferences observed remain similar to the ones obtained using a Wang-Tsiatis boundary. However, we observed that designs with Pocock stopping bounds tend to suffer much greater losses as compared to Wang-Tsiatis or O’Brien-Fleming boundaries. In general, O’Brien-Fleming designs tend to incur minimum loss compared to the other two stopping boundaries.




Supplementary Figure 1: Efficiency lost due to delay for different delay lengths for a GSD with Pocock stopping boundaries assuming uniform and linearly increasing recruitment pattern.

2 Impact of different type I and type II error values on EL

This section provides a rough idea on how changing α and β values can impact on the efficiency loss values.

The target treatment effect was assumed to remain the same as in the rest of the paper as, $\tau = 0.5$. The total recruitment time was assumed to be 24 months and efficiency lost was plotted for increasing delay length from 1 to 24 months.

Supplementary Figure 3 shows the efficiency lost due to delay for $\alpha = 0.01$ instead of $\alpha = 0.05$. Supplementary Figure 4 shows the efficiency lost for $\beta = 0.2$ instead of $\beta = 0.1$




Supplementary Figure 2: Efficiency lost due to delay for different delay lengths for a GSD with OBF stopping boundaries assuming uniform and linearly increasing recruitment pattern.

3 Efficiency loss for GSDs with Wang-Tsiatis boundary


The following tables, Supplementary Table 1 and Supplementary Table 2 give a detailed description of the EL values from the result section of the paper. The assumptions regarding the parameters of the GSD remains the same as that of the rest of the paper. i.e. we assumed the recruitment pattern to be uniform, linear as well as a mixed recruitment pattern. This section also encloses the exact EL values for a GSD with unequally spaced interims for 3 and 4 stage GSD.

The following list describes the tables given hereafter:

- Supplementary Table 1: EL assuming a Uniform recruitment pattern.
- Supplementary Table 2: EL assuming a linear recruitment pattern.
- Supplementary Table 3: EL assuming a mixed recruitment pattern for 2-stage GSD.
- Supplementary Table 4: EL assuming a mixed recruitment pattern for 3-stage GSD.
- Supplementary Table 5: EL assuming a mixed recruitment pattern for 4-stage GSD.
- Supplementary Table 6: EL assuming a mixed recruitment pattern for 5-stage GSD.
- Supplementary Table 7: EL assuming an unequally spaced GSD for a 3-stage design.
- Supplementary Table 8: EL assuming an unequally spaced GSD for a 4-stage design.



Supplementary Figure 3: Efficiency lost due to delay assuming $\alpha = 0.01$ for different delay lengths for a GSD with WT stopping boundaries assuming uniform and linearly increasing recruitment pattern.



Supplementary Figure 4: Efficiency lost due to delay assuming $\beta = 0.2$ for different delay lengths for a GSD with WT stopping boundaries assuming uniform and linearly increasing recruitment pattern.

Supplementary Table 1: Efficiency lost for Uniform recruitment for a Wang-Tsiatis GSD

No. of stages	Total recruitment period	Delay length	N_{single}	Maximum sample size	ESS	ESS_{delay}	Number of Pipeline Patients					EL
							Stage 1	Stage 2	Stage 3	Stage 4	Stage 5	
2	24	3	168.12	173.86	133.61	143.67	21.73	0				29.16
	24	6				153.74	43.46	0				58.32
	24	9				163.80	65.20	0				87.47
	24	12				173.86	86.93	0				116.63
	24	18				173.86	86.93	0				116.63
	24	24				173.86	86.93	0				116.63
3	24	3	168.12	176.49	125.30	139.97	22.06	22.1	0			34.27
	24	6				154.64	44.12	44.1	0			68.53
	24	9				165.93	66.18	58.8	0			94.90
	24	12				170.46	88.25	58.8	0			105.46
	24	18				176.49	117.66	58.8	0			119.55
	24	24				176.49	117.66	58.8	0			119.55
4	24	3	168.12	178.12	120.95	137.54	22.26	22.3	22.3	0		35.17
	24	6				154.13	44.53	44.5	44.5	0		70.33
	24	9				164.04	66.79	66.8	44.5	0		91.36
	24	12				173.96	89.06	89.1	44.5	0		112.39
	24	18				178.12	133.59	89.1	44.5	0		121.20
	24	24				178.12	133.59	89.1	44.5	0		121.20
5	24	3	168.12	179.25	118.28	135.89	22.41	22.4	22.4	22.4	0	35.32
	24	6				151.65	44.81	44.8	44.8	35.8	0	66.96
	24	9				164.66	67.22	67.2	67.2	35.8	0	93.06
	24	12				172.45	89.62	89.6	71.7	35.8	0	108.69
	24	18				178.85	134.44	107.5	71.7	35.8	0	121.53
	24	24				179.25	143.40	107.5	71.7	35.8	0	122.33

Supplementary Table 2: Efficiency lost for Linear recruitment for a Wang-Tsiatis GSD

No. of stages	Total recruitment period	Delay length	N_{single}	Maximum sample size	ESS	ESS_{delay}	Number of Pipeline Patients					EL
							Stage 1	Stage 2	Stage 3	Stage 4	Stage 5	
2	24	3	168.12	173.86	133.61	148.77	32.73	0				43.92
	24	6				166.34	70.68	0				94.83
	24	9				173.86	86.93	0				116.63
	24	12				173.86	86.93	0				116.63
	24	18				173.86	86.93	0				116.63
	24	24				173.86	86.93	0				116.63
3	24	3	168.12	176.49	125.30	148.42	27.62	37.96	0			54.01
	24	6				164.78	60.54	58.83	0			92.19
	24	9				172.61	98.75	58.83	0			110.49
	24	12				176.49	117.66	58.83	0			119.55
	24	18				176.49	117.66	58.83	0			119.55
	24	24				176.49	117.66	58.83	0			119.55
4	24	3	168.12	178.12	120.95	147.17	24.50	33.54	40.47	0		55.58
	24	6				164.86	54.35	72.41	44.53	0		93.09
	24	9				174.01	89.55	89.06	44.53	0		112.48
	24	12				177.79	130.08	89.06	44.53	0		120.51
	24	18				178.12	133.59	89.06	44.53	0		121.20
	24	24				178.12	133.59	89.06	44.53	0		121.20
5	24	3	168.12	179.25	118.28	144.78	22.34	30.47	36.71	35.85	0	53.16
	24	6				164.97	50.07	66.32	71.70	35.85	0	93.69
	24	9				176.55	83.17	107.55	71.70	35.85	0	116.92
	24	12				178.27	121.64	107.55	71.70	35.85	0	120.38
	24	18				179.25	143.40	107.55	71.70	35.85	0	122.33
	24	24				179.25	143.40	107.55	71.70	35.85	0	122.33

Supplementary Table 3: Results for EL assuming a mixed recruitment pattern for a 2 stage design

Total recruitment period	Delay length	I	N_{single}	Maximum sample size	ESS	ESS_{delay}	Number of Pipelines		EL
							Stage 1	Stage 2	
24	3	0.2	168.12	173.86	133.61	144.34	23.181	0	31.102
		0.4				145.69	26.079	0	34.99
		0.6				147.41	29.804	0	39.988
	6	0.8				149.71	34.772	0	46.653
		0.2				155.08	46.362	0	62.204
		0.4				157.76	52.157	0	69.979
		0.6				161.21	59.608	0	79.976
		0.8				165.81	69.543	0	93.306
		0.2				165.81	69.543	0	93.306
	9	0.4				169.83	78.236	0	104.97
		0.6				173.86	86.929	0	116.63
		0.8				173.86	86.929	0	116.63
		0.2				173.86	86.929	0	116.63
		0.4				173.86	86.929	0	116.63
		0.6				173.86	86.929	0	116.63
	12	0.8				173.86	86.929	0	116.63
		0.2				173.86	86.929	0	116.63
		0.4				173.86	86.929	0	116.63
		0.6				173.86	86.929	0	116.63
		0.8				173.86	86.929	0	116.63
		0.2				173.86	86.929	0	116.63
	18	0.4				173.86	86.929	0	116.63
		0.6				173.86	86.929	0	116.63
		0.8				173.86	86.929	0	116.63
0.2		173.86	86.929	0	116.63				
0.4		173.86	86.929	0	116.63				
0.6		173.86	86.929	0	116.63				
24	0.8	173.86	86.929	0	116.63				
	0.2	173.86	86.929	0	116.63				
	0.4	173.86	86.929	0	116.63				
	0.6	173.86	86.929	0	116.63				
	0.8	173.86	86.929	0	116.63				
	0.2	173.86	86.929	0	116.63				

Supplementary Table 4: Results for EL assuming a mixed recruitment pattern for a 3 stage design

Total recruitment period	Delay length	1	N_{single}	Maximum sample size	ESS	ESS_{delay}	Number of Pipelines			EL
							Stage 1	Stage 2	Stage 3	
24	3	0.2	168.12	176.49	125.3	140.95	23.532	23.53	0	36.55
		0.4				142.9	26.474	26.47	0	41.12
		0.6				144.73	26.894	30.25	0	45.38
	6	0.8				147.25	27.867	35.29	0	51.27
		0.2				156.6	47.064	47.06	0	73.10
		0.4				160.51	52.947	52.94	0	82.24
		0.6				164.08	57.149	58.83	0	90.57
		0.8				164.43	58.83	58.83	0	91.38
		0.2				166.84	70.596	58.83	0	97.01
	9	0.4				168.65	79.421	58.83	0	101.24
		0.6				170.29	87.405	58.83	0	105.06
		0.8				171.66	94.12	58.83	0	108.28
		0.2				171.66	94.12	58.83	0	108.28
	12	0.4				174.08	105.89	58.83	0	113.92
		0.6				176.49	117.66	58.83	0	119.55
		0.8				176.49	117.66	58.83	0	119.55
		0.2				176.49	117.66	58.83	0	119.55
		0.4				176.49	117.66	58.83	0	119.55
		0.6				176.49	117.66	58.83	0	119.55
	18	0.8				176.49	117.66	58.83	0	119.55
		0.2				176.49	117.66	58.83	0	119.55
		0.4				176.49	117.66	58.83	0	119.55
		0.6				176.49	117.66	58.83	0	119.55
		0.8				176.49	117.66	58.83	0	119.55
0.2		176.49	117.66	58.83	0	119.55				
24	0.4	176.49	117.66	58.83	0	119.55				
	0.6	176.49	117.66	58.83	0	119.55				
	0.8	176.49	117.66	58.83	0	119.55				
	0.2	176.49	117.66	58.83	0	119.55				

Supplementary Table 5: Results for EL assuming a mixed recruitment pattern for a 4 stage design

Total recruitment period	Delay length	1	N_{single}	Maximum sample size	ESS	ESS_{delay}	Number of Pipelines				EL
							Stage 1	Stage 2	Stage 3	Stage 4	
24	3	0.2	168.12	178.12	120.95	138.64	23.75	23.75	23.75	0	37.51
		0.4			140.86	26.72	26.72	26.72	0	42.20	
		0.6			143.82	31.81	30.53	30.53	0	48.48	
	6	0.8		144.35	24.37	29.69	35.62	0	49.61		
		0.2		155.45	47.50	47.50	44.53	0	73.14		
		0.4		158.09	53.44	53.44	44.53	0	78.74		
		0.6		161.61	62.34	61.07	44.53	0	86.21		
		0.8		162.36	54.37	65.31	44.53	0	87.79		
		0.2		166.03	71.25	71.25	44.53	0	95.57		
	9	0.4		169.99	80.15	80.15	44.53	0	103.98		
		0.6		174.32	92.88	89.06	44.53	0	113.14		
		0.8		174.05	90.00	89.06	44.53	0	112.57		
		0.2		174.52	95.00	89.06	44.53	0	113.56		
		0.4		175.62	106.87	89.06	44.53	0	115.91		
		0.6		177.17	123.41	89.06	44.53	0	119.19		
	12	0.8		177.90	131.24	89.06	44.53	0	120.74		
		0.2		178.12	133.59	89.06	44.53	0	121.20		
		0.4		178.12	133.59	89.06	44.53	0	121.20		
		0.6		178.12	133.59	89.06	44.53	0	121.20		
		0.8		178.12	133.59	89.06	44.53	0	121.20		
		0.2		178.12	133.59	89.06	44.53	0	121.20		
	18	0.4		178.12	133.59	89.06	44.53	0	121.20		
		0.6		178.12	133.59	89.06	44.53	0	121.20		
		0.8		178.12	133.59	89.06	44.53	0	121.20		
0.2		178.12	133.59	89.06	44.53	0	121.20				
0.4		178.12	133.59	89.06	44.53	0	121.20				
0.6		178.12	133.59	89.06	44.53	0	121.20				
24	0.8	178.12	133.59	89.06	44.53	0	121.20				

Supplementary Table 6: Results for EL assuming a mixed recruitment pattern for a 5 stage design

Total recruitment period	Delay length	l	N_{single}	Maximum sample size	ESS	ESS_{delay}	Number of Pipelines					EL
							Stage 1	Stage 2	Stage 3	Stage 4	Stage 5	
24	3	0.2	168.12	179.25	118.28	137.06	23.90	23.90	23.90	23.90	0	37.68
		0.4		139.41	26.89	26.89	26.89	26.89	0	42.39		
		0.6		143.38	24.14	35.85	30.73	30.73	0	50.36		
	6	0.8		144.93	22.64	32.08	35.85	35.85	0	53.47		
		0.2		153.39	47.80	47.80	47.80	35.85	0	70.44		
		0.4		156.85	53.77	53.77	53.77	35.85	0	77.40		
		0.6		162.27	54.87	66.58	61.46	35.85	0	88.27		
		0.8		165.87	50.94	69.81	71.70	35.85	0	95.48		
		9		0.2	167.26	71.70	71.70	71.70	35.85	0	98.28	
	0.4			169.86	80.66	80.66	71.70	35.85	0	103.49		
	0.6			174.45	92.19	97.31	71.70	35.85	0	112.70		
	0.8			176.63	84.91	107.55	71.70	35.85	0	117.07		
	12			0.2	174.18	95.60	95.60	71.70	35.85	0	112.17	
				0.4	177.64	107.55	107.55	71.70	35.85	0	119.11	
		0.6		178.92	136.08	107.55	71.70	35.85	0	121.68		
		0.8		178.40	124.53	107.55	71.70	35.85	0	120.64		
		18		0.2	179.25	143.40	107.55	71.70	35.85	0	122.33	
				0.4	179.25	143.40	107.55	71.70	35.85	0	122.33	
	0.6			179.25	143.40	107.55	71.70	35.85	0	122.33		
	0.8			179.25	143.40	107.55	71.70	35.85	0	122.33		
	24			0.2	179.25	143.40	107.55	71.70	35.85	0	122.33	
				0.4	179.25	143.40	107.55	71.70	35.85	0	122.33	
		0.6		179.25	143.40	107.55	71.70	35.85	0	122.33		
		0.8		179.25	143.40	107.55	71.70	35.85	0	122.33		

Supplementary Table 7: Efficiency lost for Uniform recruitment for a 3-stage GSD with unequally spaced interims

Delay length	Interim spacing	N_{single}	Maximum sample size	ESS	ESS_{delay}	Number of Pipelines			EL
						Stage 1	Stage 2	Stage 3	
3	I	168.12	175.51	125.05	139.07	21.94	21.94	0	32.55
	II		173.92	132.04	141.14	21.74	21.74	0	25.23
	III		176.20	124.24	140.27	22.03	22.03	0	36.54
	IV		176.83	130.58	148.34	22.10	17.68	0	47.31
6	I		175.51	125.05	153.09	43.88	43.88	0	65.10
	II		173.92	132.04	150.24	43.48	43.48	0	50.45
	III		176.20	124.24	156.31	44.05	44.05	0	73.08
	IV		176.83	130.58	161.29	44.21	17.68	0	81.81
9	I		175.51	125.05	164.07	65.82	58.50	0	90.59
	II		173.92	132.04	159.35	65.22	65.22	0	75.68
	III		176.20	124.24	166.25	66.08	44.05	0	95.75
	IV		176.83	130.58	174.24	66.31	17.68	0	116.30
12	I		175.51	125.05	168.97	87.75	58.50	0	101.97
	II		173.92	132.04	168.45	86.96	86.96	0	100.91
	III		176.20	124.24	176.20	88.10	44.05	0	118.42
	IV		176.83	130.58	176.83	70.73	17.68	0	123.20
18	I		175.51	125.05	175.51	117.00	58.50	0	117.15
	II		173.92	132.04	173.92	130.44	86.96	0	116.09
	III		176.20	124.24	176.20	88.10	44.05	0	118.42
	IV		176.83	130.58	176.83	70.73	17.68	0	123.20
24	I		175.51	125.05	175.51	117.00	58.50	0	117.15
	II		173.92	132.04	173.92	130.44	86.96	0	116.09
	III		176.20	124.24	176.20	88.10	44.05	0	118.42
	IV		176.83	130.58	176.83	70.73	17.68	0	123.20

Here I represents equally spaced interims; II represents the first interims takes place sooner, $(0.25, 0.5, 1)$; III represents the first interims take place later, $(0.5, 0.75, 1)$; and IV represents the first interims occur even later, after 60% and 90% of the total recruitment, $(0.6, 0.9, 1)$.

Supplementary Table 8: Efficiency lost for Uniform recruitment for a 4-stage GSD with unequally spaced interims

Delay length	Interim spacing	N_{single}	Maximum sample size	ESS	ESS_{delay}	Number of Pipelines				EL
						Stage 1	Stage 2	Stage 3	Stage 4	
3	I	168.12	177.21	120.44	136.51	22.152	22.152	22.152	0	33.703
	II		175.58	124.36	136.33	21.948	21.948	21.948	0	27.361
	III		177.64	119.14	136.28	22.205	22.205	22.205	0	34.99
6	I	168.12	177.21	120.44	152.58	44.304	44.304	44.304	0	67.406
	II		175.58	124.36	148.3	43.896	43.896	43.896	0	54.72
	III		177.64	119.14	151.52	44.409	44.409	35.527	0	66.117
9	I	168.12	177.21	120.44	162.04	66.456	66.456	44.304	0	87.243
	II		175.58	124.36	160.28	65.843	65.843	65.843	0	82.08
	III		177.64	119.14	163.93	66.614	66.614	35.527	0	91.45
12	I	168.12	177.21	120.44	171.49	88.607	88.607	44.304	0	107.08
	II		175.58	124.36	167.7	87.791	87.791	70.233	0	99.046
	III		177.64	119.14	172.02	88.819	71.055	35.527	0	107.97
18	I	168.12	177.21	120.44	177.21	132.91	88.607	44.304	0	119.08
	II		175.58	124.36	174.87	131.69	105.35	70.233	0	115.43
	III		177.64	119.14	177.64	106.58	71.055	35.527	0	119.43
24	I	168.12	177.21	120.44	177.21	132.91	88.607	44.304	0	119.08
	II		175.58	124.36	175.58	140.47	105.35	70.233	0	117.05
	III		177.64	119.14	177.64	106.58	71.055	35.527	0	119.43

Here I represents equally spaced interims; II represents interims done at 20, 40, 60 and 100% of the total sample size, i.e. the first interim is done sooner than an equally spaced design; III represents interims done at 40,60,80 and 100% of the total sample size, i.e. the first and subsequent interims are pushed to the latter end of the design.